Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
तुलना करने के लिए मीट्रिक्स | GLPG | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधGLPGपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −1,235.7x | −0.2x | −0.5x | |
PEG अनुपात | 18.84 | −0.01 | 0.00 | |
क़ीमत/बुक | 0.5x | 1.0x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 5.7x | 5.1x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 150.9% | 53.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 9.5% | 9.6% | अनलॉक करें |